• Ave. 31 No. 15802 between 158 y 190, Cubanacán, Playa, Havana. C.P. 11600, P.O. Box 6162
  • webmaster@cigb.edu.cu
  • (53) 7-2504101; (53) 7-2716022

BioNCiD 2027

  Home   : :   BioNCiD 2027

INVITATION

On behalf of the Organizing Committee, we are pleased to invite you register and participate in the 5th International Congress on Nonclinical Biopharmaceutical Development, BioNCiD 2027, organized by the Center for Genetic Engineering and Biotechnology (CIGB) of Havana, Cuba, to be held from May 23 to 27, 2027, in Varadero, Cuba.

BioNCiD, a premier international forum dedicated to advancing nonclinical development in biopharmaceutical sciences, will bring together leading experts, researchers, and industry professionals from around the world to share the latest scientific advances, regulatory updates, and innovative approaches.

At BioNCiD 2027, you will have the opportunity to interact with specialists from various countries, present your research and projects, network with colleagues and industry leaders, and participate in discussions tailored to current challenges and trends in nonclinical development.

The previous edition, BioNCiD 2025, brought together approximately 100 highly qualified specialists in various areas of preclinical development from 10 countries, including Cuba, Canada, Mexico, the United States, Spain, Italy, Vietnam, Russia, Brazil, and Colombia.

For this upcoming edition, one of our goals is to increase the number of participants and the diversity of countries.

BioNCiD 2027 will cover the following topics:

  1. Nonclinical Development programs for drugs and biopharmaceuticals products
  2. Advances in pharmacokinetics and toxicology
  3. Trends in the evaluation of drug-drug interactions, drug-biotechnological products and microbiota
  4. Update of the nonclinical regulatory framework
  5. Applications of Artificial Intelligence in the Nonclinical Development of Biopharmaceutical Products
  6. Staff training and accreditation of facilities
  7. Institutional Animal Care and Use Committee (IACUC) and its role in Nonclinical Development.
  8.  Animal and human welfare: behavioral management and implementation of culture of care according to nonclinical regulatory requirements and application of 3Rs
  9. Domestic cage monitoring technologies, improved nonclinical to clinical translation
  10. Animal models: development and use, challenges and perspectives
  11. Zebra fish. The rising star of animal testing.
  12. Alternative methods to the use of animals

On this 5th edition, BioNCiD will host a symposium on OMICS and Nonclinical Studies, which will address topics related to the biotechnology industry and the use of mass spectrometry for drug discovery and development.

Includes: Methods for sample preparation, characterization of peptides/proteins/conjugates, crosslinking, pharmacokinetic studies, biomarkers identification, technologies for OMICS data generation, mass spectra data processing and database search engines, computational proteomics, functional network analysis, integrative OMICS data analysis, and system biology based bioinformatics software development.

Abstract submission deadline: April 30, 2027.

Acceptance deadline: April 30, 2027.

We sincerely hope you can participate and contribute your valuable experiences and knowledge to the development of this scientific field.

Sincerely,

Jorge Castro Velazco, PhD

Congress President

e-mail: jorge.castro@cigb.edu.cu

Congress e-mail: BioNCiD@cigb.edu.cu

 

 

Details

Start:
23 mayo 2027
End:
27 mayo 2027
Website:
/event/cancer-2027/

Venue

Varadero, Cuba

Documentation

Organizers

Jorge Castro Velzaco, PhD.
Phone:
(+53) 72716022, ext. 2300
Email:
jorge.castro@cigb.edu.cu
Lizet Aldana Velazco, MSc.
Phone:
(+53)7216022, ext. 2308
Email:
lizet.aldana@cigb.edu.cu

Scientific Comittee

Jorge Castro Velzaco, PhD.
Phone:
(+53) 72716022, ext. 2300
Email:
jorge.castro@cigb.edu.cu
Lizet Aldana Velazco, MSc.
Phone:
(+53)7216022, ext. 2308
Email:
lizet.aldana@cigb.edu.cu

Instructions for preparing abstracts for oral and poster presentations

Abstracts should be sent to the following email address: bioncid@cigb.edu.cu and will be published in the form of a summary book.

All submitted abstracts will be reviewed by the Organizing Committee to select them for oral or poster presentations. Poster presentations will be electronic.

Abstracts for both types of presentations should be emailed to the organizers as follows:

  1. Word Length: Abstracts should not exceed 300 words.
  2. Font and Spacing: Arial 10pt font and single-line spacing.
  3. Title: 130 characters (not including spaces) and bold.
  4. Authors: Last name only, followed by a space and initials (e.g., Castro R1). The number of authors is unlimited, but the primary author must be distinguished.
  5. Affiliations: Each author must be listed by department, institution, city, and country.
  6. Title alignment: Centered
  7. Author list alignment: Centered
  8. Author affiliation alignment: Justified
  9. Abstract text alignment: Justified
  10. Tables, figures, and graphs: Tables, figures, and graphs will not be included.

Contact: The email address of the presenting author is required; this information must appear below the abstract.

Language: Abstracts for oral and poster presentations must be written in English.

Abstract submission deadline: April 30, 2027.

Acceptance deadline: April 30, 2027.